Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/20/25
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewsWire • 02/20/25
Curious about Travere (TVTX) Q4 Performance? Explore Wall Street Estimates for Key MetricsZacks Investment Research • 02/17/25
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewsWire • 02/13/25
Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseZacks Investment Research • 02/13/25
Travere Therapeutics Skyrockets After Reaching FDA Deal For Kidney Disease DrugInvestors Business Daily • 02/11/25
Wall Street Analysts Believe Travere (TVTX) Could Rally 42.56%: Here's is How to TradeZacks Investment Research • 01/08/25
Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/06/25
Homocystinuria Therapeutics Market Research 2024: Insights About 3+ Companies and 3+ Pipeline Drugs Featuring Travere Therapeutics and Syntis BioGlobeNewsWire • 12/18/24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXAccesswire • 11/27/24
Kidney Disease Leader Travere Therapeutics Pulls Back To Key LevelInvestors Business Daily • 11/19/24
Travere (TVTX) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 10/31/24
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 10/31/24
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024GlobeNewsWire • 10/26/24
Wall Street Analysts See a 26.27% Upside in Travere (TVTX): Can the Stock Really Move This High?Zacks Investment Research • 10/23/24
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA NephropathyGlobeNewsWire • 10/17/24